Merck & Co. vs Pfizer vs Amgen and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD_BILLIONS. In Q2 2026: Merck & Co. 16.607, Pfizer 15.034, Amgen 10.054, Roche 17.5245.
* Roche reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, Merck & Co., Pfizer, Amgen, Roche.| Metric | Merck & Co. | Pfizer | Amgen | Roche |
|---|---|---|---|---|
| Market Cap | $366.84B | $163.69B | $226.05B | $340.00B |
| Revenue | $16.61B | $15.03B | $10.05B | $35.05B |
| Cost of Revenue | $4.39B | $4.09B | $2.81B | $9.21B |
| Gross Profit | $12.21B | $10.94B | $7.24B | $25.84B |
| Operating Income | $-683.00M | $4.71B | $3.51B | $10.90B |
| Net Income | $-1.33B | $-246.00M | $2.38B | $7.93B |
| R&D Expense | $9.74B | $2.81B | $1.87B | $8.35B |
| Earnings Per Share | -$0.54 | -$0.04 | $4.37 | $1.23 |
| Gross Margin | 73.5% | 72.8% | 72.0% | 73.7% |
| Operating Margin | -4.1% | 31.3% | 35.0% | 31.1% |
| Net Profit Margin | -8.0% | -1.6% | 23.6% | 22.6% |
| Free Cash Flow | $4.48B | $302.00M | $3.49B | $6.46B |
| Cumulative Free Cash Flow | $249.70B | $356.70B | $169.18B | $305.80B |
| Operating Cash Flow | $5.37B | $835.00M | $4.00B | $8.28B |
| Cash & Equivalents | $6.85B | $976.00M | $13.99B | $6.13B |
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.